Aspira Women’s Health (AWH) announced that the company received written notice from Nasdaq indicating that the Nasdaq Hearings Panel has determined to delist the company’s shares from Nasdaq due to the company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5M in stockholders’ equity for continued listing on the Nasdaq Capital Market. Trading in the company’s shares of common stock will be suspended on Nasdaq effective with the open of trading on Thursday, April 17.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AWH:
- Aspira Women’s Health files to sell 354,988 shares of common stock for holders
- Aspira Women’s Health Secures $2M Equity Agreement
- Aspira appoints Jeffrey Cohen, Cindy Hundorfean, Jack Fraser to board
- Aspira Women’s Health Signs CEO Employment Agreement
- Aspira Women’s Health receives $1.5M milestone payment from ARPA-H
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue